Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial.

BMC Med · 2025 · PMC12060414 · PMID 40336058

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

marginal significancep = 0.063so close (0.05 < p ≤ 0.1)

Combination therapy showed a 10% decrease in liver fat, the greatest reduction among the groups, albeit with marginal significance for the three-group difference ( p = 0.063) (Table 2 ).

also in 3,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.